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No standard of care for pure red cell aplasia (PRCA) after major ABO-incompatible hematopoietic stem cell
transplantation (HSCT) has been established. We conducted a retrospective cohort study to learn the efﬁcacy
and outcome of treatment for PRCA. One hundred forty-ﬁve recipients who showed delayed recovery of
erythropoiesis and survived >100 days after transplantation without early disease progression were selected
from 2846 records of major ABO-incompatible transplantation in the registry database in Japan, and detailed
data of 46 recipients were collected. Treatment of PRCA, such as rapid tapering of calcineurin inhibitors,
corticosteroids, or additional immunosuppressants, was given to 22 patients but not to the other 24 patients.
The overall response rate of the treatment group was 54.5%. The number of days from diagnosis of PRCA to
recovery of reticulocytes >1% and the cumulative number of red blood cell transfusions were not signiﬁcantly
different between the 2 groups. Infections accounted for the death of 7 of 11 patients in the treatment group.
Univariate analysis identiﬁed 5 variables inﬂuencing survival, including graft-versus-host disease, disease
progression, and treatment of PRCA; disease progression remained as the only factor negatively affecting
survival by multivariate analysis. The present study could not provide supportive evidence for the beneﬁcial
effects of treatment for PRCA after major ABO-mismatched HSCT.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION several risk factors for the development of PRCA after major
Pure red cell aplasia (PRCA) is a syndrome characterized
by anemia, reticulocytopenia, and an absence of erythro-
blasts from otherwise normal bone marrow. The causes and
courses of this syndrome are highly variable, and the man-
agement of this anemia depends on its underlying mecha-
nisms and diseases [1-7].
Incompatibility of ABO blood antigens is not supposed to
be a barrier to allogeneic hematopoietic stem cell trans-
plantation (HSCT). However, delayed recovery of erythro-
poiesis is one of the major complications in allogeneic HSCT
from major ABO-incompatible donors [8]. Controversy still
exists regarding the inﬂuence of ABO incompatibility on the
outcome of allogeneic HSCT [9-14]. Incompatible hemag-
glutinins in recipients are attributed to the delayed recovery
of reticulocyte counts and hypoplasia of erythroblasts in
bone marrow [15,16]. Previous studies have demonstratededgments on page 1031.
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ible anti-A hemagglutinin in recipients [8,17], the use of
a reduced-intensity preparatory regimen [18,19], the use of
cyclosporine, use of sibling donors, or the absence of acute
graft-versus-host-disease (GVHD) [20].
Few publications exist on the successful treatment of this
PRCA, including rapid tapering of calcineurin inhibitors [21],
corticosteroids [22,23], donor lymphocyte infusion [24], rit-
uximab [25,26], erythropoiesis-stimulating agents [27,28],
antilymphocyte globulin [29], immunoadsorption [30,31],
plasma exchange [32], and mesenchymal stem cells [33,34].
However, no standard of care for PRCA after allogeneic HSCT
frommajor ABO-incompatible HSCT has been established. To
learn the efﬁcacy and long-term outcome of treatment for
PRCA after allogeneic HSCT from major ABO-incompatible
donors, we conducted a retrospective cohort study and
established a patient cohort of 46 patients with this PRCA.
METHODS
Study Design
The present study was conducted as a retrospective observational study.
It was approved by the Institutional Review Board of Akita University
Graduate School of Medicine and the Data Management Committees of theTransplantation.
Figure 1. Diagram for establishing the patient cohort. To obtain the study
cohort, patients who achieved neutrophil engraftment with delayed recovery
of erythropoiesis were selected from 2846 recipients of major ABO-
incompatible grafts. Patients who died before 100 days or whose underlying
malignancies relapsed or progressed within the ﬁrst 6 months were excluded.
Questionnaires were sent to transplant centers, and 48 recipients were
identiﬁed as having PRCA, whereas 51 patients were not diagnosed with
PRCA.
Table 1
Patient Characteristics
Category and Variable No. of Patients
Total number of patients 46
Age, yr 10-66 (median 49)
Sex
Male 24
Female 22
Disease
AML 23 (14 CR, 7 non-CR, 2 unknown)
MDS 10
ALL 2 (2 CR)
CML 1
Unclassiﬁed leukemia 1
Aplastic anemia 7
Lymphoma 1
EBV-associated disease 1
Donor
Related 24
Unrelated 22
Graft
Bone marrow 33
Peripheral blood stem cell 13
Cord blood 0
Incompatible hemagglutinin
Anti-A 28
Anti-B 12
Both 6
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myeloid
leukemia; EBV, Epstein-Barr virus; CR, complete remission.
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Data Collection
The patient cohort was selected from the registry database of the
Transplantation Registry Uniﬁed Management Program [35], which covered
both adult and pediatric transplantation using all kinds of graft sources in
Japan. In an attempt to evaluate the efﬁcacy of treatment for PRCA and the
long-term outcome, 145 recipients, who achieved neutrophil engraftment
with delayed recovery of erythropoiesis and survived >100 days after
transplantation without disease relapse or progression within the ﬁrst 6
months, were selected from 2846 records of major ABO-incompatible allo-
geneic transplantation from 2003 to 2007 (Figure 1). Delayed recovery of
erythropoiesis was noted when the posttransplantation days to recover>1%
reticulocytes exceeded 60 days. Neutrophil recovery was deﬁned by an
absolute neutrophil count of at least .5  109/L for 3 consecutive days.
The ﬁrst questionnaires were sent to transplantation centers, and the
response rate was 68.3% (99 of 145 recipients). Forty-eight recipients were
identiﬁed as having PRCA. Detailed transplantation data from 46 of those 48
recipients were then collected by sending second questionnaires. Second
questionnaires did not collect information on the presence of human
parvovirus B19 genome in blood in the present study.
Deﬁnition
Posttransplantation PRCA was deﬁned as anemia with low reticulocyte
counts (<1%) in peripheral blood for more than 60 days after transplantation
in association with neutrophil recovery and a lack of erythroblasts in bone
marrow. Diagnosis of PRCA was made by hematologists in each trans-
plantation center. Acute and chronic GVHD was diagnosed and graded
according to consensus criteria [36,37]. Calcineurin inhibitors were gener-
ally given from day1 through day 50 of transplantation at the full dose and
then tapered at the pace of 5% per week and stopped 6 months after
transplantation if recipients did not have active severe GVHD. Rapid
tapering of calcineurin inhibitors was deﬁned as a reduction in drug doses
exceeding >5% per week.
The deﬁnition of a clinical response to treatment for PRCA and the
timing of evaluation were previously reported [3-5]. Complete remission,
partial remission, and no response were deﬁned as the achievement of
normal hemoglobin levels without transfusion, the presence of anemia
without transfusion dependence, and the continued need for transfusions,
respectively.
Statistical Analysis
All statistical analysis was performed using PASW Statistics 18 (SPSS,
Tokyo, Japan). Survival time was estimated by the Kaplan-Meier method,
and comparison between the two groups was made by the log-rank test.
Comparisons of parametrical data from one group or the other were made
with non-paired 2-tailed t-tests after the equality of variances was deter-
mined by Levene’s test. Comparisons of categorical data were made with
Pearson’s chi-square test unless otherwise stated. Multivariate analyses
were performed using the multiple logistic regression model.RESULTS
Patient Characteristics
Characteristics of patients with PRCA after ABO major
incompatible HSCT are shown in Table 1. No patient received
pretransplantation removal of antidonor hemagglutinins
(data not shown). None of the patients with PRCA had cord
blood transplantation. Of 1182 patients who received cord
blood transplantation frommajor ABO-mismatched grafts,17
patients were selected as potential candidates for PRCA. The
questionnaires were sent to the transplantation centers
where those patients were treated, and responses were ob-
tained from all centers. None of those 17 patients was diag-
nosed as having PRCA. Incompatible hemagglutinins were
anti-A in 28 patients, anti-B in 12, and both in 6 patients.Initial Treatment of PRCA and Outcome of Anemia
Treatment of PRCA other than transfusion was performed
in 22 patients (treatment group) but not in the other 24
patients (nontreatment group) (Tables 2 and 3). Corticoste-
roids were given as an initial treatment in 12 patients, and
rapid tapering of calcineurin inhibitors was performed in
8 patients. Rituximab was given in 1 patient and erythro-
poietin in 1 patient. In 7 of 12 patients who were given
corticosteroids for treatment of PRCA, corticosteroids were
started before day 60 because of severe acute GVHD.
Response to the initial treatment was observed in 6 of
12 patients receiving corticosteroids (4 complete response, 2
partial response) and 2 of 8 patients who had rapidly tapered
calcineurin inhibitors (2 complete response) (patients 13 and
14). None of the patients receiving rituximab (n ¼ 1; patient
21) or erythropoietin (n ¼ 1; patient 22) responded.
Secondary therapy including rituximab, additional im-
munosuppressants, or donor lymphocyte infusion was given
to 8 patients with a 50% response rate. The overall response
rate of treatment for PRCA was 54.5%. Four of 10 patients
who did not show any responses to treatment spontane-
ously became transfusion-independent. Red cell transfusion
Table 2
Response and Outcome of Treatment for Post-Transplant PRCA
UPN Initial Treatment
and Response
Salvage Therapy Acute GVHD
Grades II-IV
Chronic GVHD Reticulocytes >1% Outcome
of PRCA
Outcome Cause of Death
1 CS (215-828), CR No No Reached (235) CR Alive (2057)
2 CS (38-718), CR Yes, grade II Yes, limited Reached (187) CR Dead (718) Infection
3 CS (50-309), CR No No Reached (130) CR Alive (1364)
4 CS (51-94), CR Yes, grade II No Reached (73) CR Dead (1827) PD
5 CS (50-418), CR Yes, grade II No Reached (149) CR Alive (937)
6 CS (56-130), CR Yes, grade II Yes, limited Reached (137) PR Alive (165)
7 CS (53-168), PR Yes, grade II No Reached (113) PR Dead (291) Infection
8 CS (140-225), NR RTX (250), CR No No Reached (350) CR Alive (1509)
9 CS (29-191), NR MMF (179-333), NR Yes, grade IV Not assessable Reached (83) NR Dead (341) Organ failure
10 CS (36-128), NR Yes, grade II No Not reached PR Dead (328) Infection
11 CS (98-344), NR No No Not reached NR Alive (344)
12 CS (111-184), NR No Yes, extensive Not reached NR Alive (184)
13 CNI rapid tapering, CR No No Reached (144) CR Alive (1003)
14 CNI rapid tapering, CR Yes, grade II No Reached (422) CR Alive (1437)
15 CNI rapid tapering, NR Yes, grade III Yes, extensive Not reached NR Dead (743) Infection
16 CNI rapid tapering, NR CS (122-239), CR No Yes, extensive Reached (201) CR Dead (828) GVHD
17 CNI rapid tapering, NR CS (105-991), PR No Yes, extensive Reached (380) PR Dead (991) Infection
18 CNI rapid tapering, NR DLI (174), NR No No Not reached Unknown Dead (220) PD
19 CNI rapid tapering, NR EPO (56), NR No No Reached CR Alive (1081)
20 CNI rapid tapering, NR EPO (95), NR
DLI (132), NR
RTX (194), NR
CsA (530-587), CR
No Yes, limited Reached (530) Unknown Dead (811) Infection, organ
failure
21 RTX (319), NR AZT (359-365), NR
CS (402-898), NR
No Yes, limited Reached (480) NR Dead (898) Infection
22 EPO (64), NR Yes, grade II Yes, limited Reached PR Alive (1443)
CS indicates corticosteroids; CNI, calcineurin inhibitor; FK506, tacrolimus; CsA, cyclosporine A; EPO, erythropoietin; RTX, rituximab; DLI, donor lymphocyte
infusion; MMF, mycophenolate mofetil; AZT, azathiopurine; CR, complete response; PR, partial response; NR, no response; PD, progression of underlying
disease; UPN, unique patient number.
The numbers in parenthesis indicate posttransplantation days when each drug was given.
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the treatment group and nontreatment group, respectively,
with a signiﬁcant difference (P ¼ .008, Pearson’s chi-square
test).
Efﬁcacy of Treatment for PRCA
Days from diagnosis of PRCA to recovery of reticulocytes
>1% and cumulative doses of red blood cell transfusionTable 3
Outcome of posttransplantation PRCA Receiving No Treatment
UPN Acute GVHD
Grades II-IV
Chronic GVHD Reticulocytes >1%
23 No No Reached (67)
24 No No Reached (78)
25 No No Reached (88)
26 No No Reached (99)
27 No No Reached (112)
28 No No Reached (118)
29 No Yes, extensive Reached (146)
30 No No Reached (164)
31 No No Reached (178)
32 No Yes, extensive Reached (180)
33 No No Reached (191)
34 No No Reached (229)
35 No Yes, limited Reached (234)
36 Yes, grade II Yes, limited Reached (245)
37 No No Reached (250)
38 Yes, grade III Yes, extensive Reached (253)
39 No Yes, limited Reached (322)
40 No No Reached (348)
41 No No Reached (365)
42 No Yes, limited Reached (387)
43 No No Reached (389)
44 No No Reached (400)
45 Yes, grade II No Reached (515)
46 No Yes, limited Not reached
CR indicates complete response; PR, partial response; NR, no response; PD, progre
Numbers in parenthesis indicate posttransplantation days.during this period were not signiﬁcantly different between
the two groups (Figure 2). The average number of red blood
cell transfusions in total was 67.6 units (range, 10 to 216) and
65.3 units (range, 12 to 454) in the treatment group and
nontreatment group, respectively. One unit of packed red
cells is prepared from 200 mL of blood in Japan. No signiﬁ-
cant difference occurred in the number of red blood cell
transfusions between the two groups (P ¼ .916; t-test). TheOutcome of PRCA Outcome Cause of Death
CR Alive (1348)
CR Alive (1580)
CR Alive (2004)
CR Dead (533) Organ failure
CR Alive (505)
CR Alive (1279)
CR Alive (919)
CR Alive (952)
CR Alive (1501)
CR Alive (2326)
PR Dead (701) PD
CR Alive (2244)
CR Alive (1786)
CR Alive (1789)
CR Alive (1209)
CR Alive (1109)
CR Alive (1730)
CR Alive (1911)
CR Alive (1785)
CR Alive (731)
CR Alive (498)
CR Alive (723)
CR Alive (1049)
NR Alive (1994)
ssion of underlying disease.
Figure 2. Recovery of erythropoiesis. Days from diagnosis of PRCA to recovery
of reticulocytes >1% were compared between the intervention and noninter-
vention groups, showing no signiﬁcant difference (log rank .663).
Table 4
Comparison of Backgrounds between Treatment and Nontreatment Groups
Category and Variable Treatment
(n ¼ 22)
Nontreatment
(n ¼ 24)
P*
Age, yr 10-66 (42.7) 11-62 (42.8) .982
Sex .369
Male 13 11
Female 9 13
Severity of anemiay
Red blood cell, 104/mL 143-347 (242) 196-350 (271) .038
Hemoglobin, g/dL 4.1-10.1 (7.2) 5.9-10.3 (8.2) .024
Hematocrit, % 12.2-30.2 (21.1) 17.4-31.0 (24.0) .025
Underlying disease .487
AML 10 13
ALL 2 0
MDS 5 5
CML 1 0
Unclassiﬁed leukemia 0 1
Lymphoma 1 0
Aplastic anemia 3 4
EBV-associated disease 0 1
Donor .382
Related 10 14
Unrelated 12 10
Graft .243
Bone marrow 14 19
Peripheral blood stem cell 8 5
Serological HLA compatibility .339
Matched 21 21
Mismatched 1 3
Genotypical HLA
compatibility
.821
Matched 18 19
Mismatched 4 5
Conditioning .536
Myeloablative 9 12
Nonmyeloablative 13 12
Calcineurin inhibitor .758
Cyclosporine 12 12
FK506 10 12
MTX .255
Yes 19 23
No 3 1
Acute GVHD grades II-IV .013
No 12 21
Yes 10 3
Chronic GVHD .687
No 12 16
Yes 9 8
Not assessable 1 0
Incompatible hemagglutinin
titerz
IgG, mg/dL, range (median) 2-1024 (128) 2-1024 (64) .252
IgM, mg/dL, range (median) 4-256 (16) 2-64 (16) 1.000
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myeloid
leukemia; EBV, Epstein-Barr virus; FK506, tacrolimus.
* Comparison was made with Pearson’s chi-square test unless otherwise
stated.
y Student’s t-test.
z Mann-Whitney’s U-test.
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calculated as the total units of red blood cell transfusion
divided by the posttransplantation days until the last red
blood cell transfusion, were .24 (.09 to .64) and .22 (.10 to
032) units per day in the treatment and nontreatment
groups, respectively, with no signiﬁcant difference (P¼ .484).
Comparison of the Proﬁles Between the Treatment and
Nontreatment Groups
Wecompared thebackgroundproﬁles of patients receiving
treatment of PRCA with those not receiving treatment
(Table 4). Hemoglobin levels were lower in the treatment
group than in thenontreatment group, although incompatible
hemagglutinin titers at diagnosis of PRCA were not different.
There were no signiﬁcant differences in age, underlying
diseases, type of donor and graft, HLA compatibility, condi-
tioning regimen, immunosuppressive drugs, acute GVHD, and
chronic GVHD between the 2 groups, although grades II to IV
acute GVHD was more frequently found in the treatment
group (P ¼ .013).
Survival of PRCA Patients
The estimated median overall survival of all 46 PRCA
patients has not been reached (Figure 3, left). The median
overall survival time of patients receiving the intervention
was 991 days, whereas estimated median overall survival of
the nonintervention group has not been reached (Figure 3,
middle and right). Two and 11 deaths were observed in the
nontreatment group and treatment group, respectively.
Causes of death in the treatment group were infections in 6
patients, infection plus organ failure in 1, organ failure in 1,
GVHD in 1, and disease progression in 2 patients (Table 2).
Thus, infections accounted for the death of 7 patients in the
treatment group. Causes of death in the nontreatment group
included organ failure and disease progression in each
patient, respectively (Table 3).
Univariate analysis identiﬁed 5 variables attributable to
the death of PRCA patients, including male gender, grades II
to IV acute GVHD, chronic GVHD, disease progression, and
treatment of PRCA (Table 5). These 5 variables were then
incorporated into the multiple logistic regression model.
Multivariate analysis revealed that progression of thedisease remained as the only factor negatively affecting
overall survival (P ¼ .028) (Table 6). Likewise, univariate
analysis for risk factors for nonrelapse mortality was per-
formed showing that 3 variables, including male gender,
chronic GVHD, and treatment of PRCA, were risk factors.
With these 3 variables, multiple logistic regression analysis
was done and treatment of PRCA remained as the signiﬁcant
risk factor (P ¼ .036).DISCUSSION
In the present retrospective cohort study, we demon-
strated for the ﬁrst time that treatment of PRCA after
Figure 3. Overall survival of PRCA patients. Kaplan-Meyer estimates of survival for PRCA patients are shown.
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not improve the recovery of erythropoiesis or decrease the
red blood cell transfusion requirement. Although the resultsTable 5
Univariate Analysis of Categorical Factors Inﬂuencing Survival
Category and Variable n Death P*
Gender .035
Female 22 3
Male 24 10
Underlying disease .327
AML 23 6
ALL 2 0
MDS 10 6
CML 1 0
Unclassiﬁed leukemia 1 0
Lymphoma 1 0
Aplastic anemia 7 1
EBV-associated disease 1 0
Donor .608
Related 24 6
Unrelated 22 7
Graft .335
Bone marrow 33 8
Peripheral blood stem cell 13 5
Serological HLA compatibility .880
Matched 42 12
Mismatched 4 1
Genotypical HLA compatibility .203
Matched 37 12
Mismatched 9 1
Conditioning .539
Myeloablative 21 5
Nonmyeloablative 25 8
GVHD prophylaxis
Cyclosporine 22 7 .608
FK506 24 6 .608
MTX 42 11 .312
Acute GVHD grades II-IV .091
No 33 7
Yes 13 6
Chronic GVHD .197
No 28 6
Yes 17 6
Not assessable 1 1
Disease progression .003
No 36 6
Yes 9 6
Not assessable 1 1
Treatment of PRCA .002
No 24 2
Yes 22 11
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; ALL, acute lymphoblastic leukemia; CML, chronic myeloid
leukemia; EBV, Epstein-Barr virus; FK506, tacrolimus; MTX, methotrexate.
* P values were calculated by Pearson’s chi-square test.have to be interpreted very carefully because of the ret-
rospective nature of the study and the relatively small
number of PRCA patients, our ﬁndings have important clin-
ical implications.
Failure to demonstrate the beneﬁcial effects of treatment
on recovery of erythropoiesis in these PRCA patients may be
debated by raising the possibility that the treatment group
included more patients with severe anemia. This is partly
true because average hemoglobin levels at diagnosis of PRCA
were signiﬁcantly lower in the treatment group than in the
nontreatment group (Table 2). However, because the days
from diagnosis of PRCA to the recovery of reticulocytes >1%
were not different between the 2 groups seems to support
the hypothesis that treatment of PRCA does not improve the
recovery of erythropoiesis in bone marrow.
There are several potential arguments for apparently
inferior survival of PRCA patients receiving treatment of
PRCA. Severe acute GVHD and chronic GVHD may be con-
founding variables for treatment in PRCA and survival of
post-transplantation patients because corticosteroids could
be used for treatment of severe acute GVHD and chronic
GVHD, and both are well-known adverse risk factors on
survival. There were more patients with grades II to IV acute
GVHD in the treatment group than in the nontreatment
group (Table 2). However, multiple logistic regression anal-
ysis revealed that neither acute GVHD nor chronic GVHDwas
a signiﬁcant hazard in the present patient cohort (Table 3).
We are not ready to provide a reasonable explanation forTable 6
Multiple Logistic Regression Analysis of Risk Factors for Survival of Patients
with posttransplantation PRCA
Covariate OR 95% CI P
Sex .114
Female 1.00
Male 1.81 .42 to 4.04
Acute GVHD grades II-IV .349
No 1.00
Yes 1.00 1.10 to 3.10
Chronic GVHD .934
No 1.00
Yes .08 1.86 to 2.02
Treatment of PRCA .066
No 1.00
Yes 1.93 .13 to 3.99
Disease progression .028
No 1.00
Yes 2.31 .25 to 4.37
OR indicates odds ratio.
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overall survival, although this factor was eventually judged
as an insigniﬁcant hazard by multivariate analysis.
Infections accounted for the death of 7 of 11 patients in
the treatment group, whereas 2 deaths were observed in the
nontreatment group, neither of which was attributed to
infection. In particular, all 4 patients who had developed
chronic GVHD after rapid tapering of calcineurin inhibitors
died of infection or GVHD (Table 2). The use of additional
immunosuppressive agents might be associated with the
death of PRCA patients.
Corticosteroids were given to 12 patients, and 7 of those
patients had severe acute GVHD. In these patients, it is
difﬁcult to deﬁne the purpose of corticosteroid therapy
given for PRCA or GVHD. Questionnaires were designed to
ask physicians whether any intervention was given to treat
PRCA and what type of therapy was given. Therefore, the
use of corticosteroids was counted as an intervention for
PRCA based on the physician’s intention, but corticosteroid
therapy could also have been given to treat concurrent acute
GVHD.
Absence of acute GVHD has been reported as 1 risk factor
for PRCA after major ABO-mismatched HSCT, suggesting the
presence of graft-versus-plasma cell effect [20]. Corticoste-
roid therapy has been reported to be effective to ameliorate
anemia in some cases of PRCA after transplantation, whereas
corticosteroids could also suppress graft-versus-plasma
cell effect resulting in the survival of host-derived incom-
patible hemagglutinins. Thus, the efﬁcacy of corticosteroids
for anemia is not predictable in PRCA patients with acute
GVHD.
In the present study, different interventions for PRCA
were included together in the treatment group for analyzing
the data. Although various treatment options have been re-
ported for patients with PRCA after major ABO-incompatible
HSCT, there is no consensus regarding which one is better
than the other, because of the small number of patients in
most studies and absence of prospective studies. Also, there
is no recommendation whether any treatment should be
given to PRCA patients in this clinical setting. Any previously
reported treatment for PRCA has a potential risk for adverse
events, including opportunistic infections or exacerbation of
GVHD. The principal aim of the present study was to learn
the efﬁcacy of treatment for PRCA in general, and thus all
treatment modalities were included in the treatment group
for data analysis.
Previous studies have shown that the validity of the
logistic model becomes problematic when the number of
events per variable analyzed becomes small. Peduzzi et al.
[38] reported that for event per variable less than 10 the
regression coefﬁcients are biased. This appears to be the case
with our study, suggesting the requirement of a large
number of patients in future studies.
In this patient cohort, no PRCA patient was reported with
cord blood stem cell transplantation from major ABO-
incompatible donors. Tomonari et al. [39] reported that
none of the 39 patients receiving major ABO-incompatible
cord blood cells developed PRCA. Although the reason re-
cipients of cord blood cells did not develop PRCA is unknown,
susceptibility of erythroid precursor cells to incompatible
isohemagglutinin-induced cytotoxicity may be different
between cord blood stem cells and other stem cell grafts.
Reduction of incompatible isohemagglutinin titers such as
plasma exchange before transplantation has previously been
tried with various results, but there has been no speciﬁcrecommendation so far [40,41]. In our patient cohort, no
patient with PRCA received this practice.
In summary, we could not demonstrate any beneﬁcial
effects of treatment on the recovery of PRCA after allogeneic
HSCT from major ABO-incompatible donors. However,
extracorporeal treatment was not included in the treatment
options of our patient cohort [32]. The present study has
several limitations, including a small sample size, reporting
bias resulting from the retrospective study, the lack of
parvovirus B19 data, heterogeneity of underlying diseases
and its status, the treatment received, and so on. Thus, awell-
designed prospective study should be performed to clarify
the role of interventions for PRCA, including rapid tapering of
calcineurin inhibitors after major ABO-mismatched hema-
topoietic cell transplantation.ACKNOWLEDGMENTS
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